Transgene grants Novartis TG4010 option

Transgene S.A. (Euronext:TNG) granted Novartis AG (NYSE:NVS; SIX:NOVN) an option to obtain exclusive, worldwide rights to TG4010. Transgene plans to start a Phase IIb/III trial of TG4010 in patients with non-small cell lung cancer (NSCLC) by year end. Data from the Phase IIb portion of the trial are expected in 1Q12, after which Novartis will have a 90-day period to exercise its option. ...